Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …

Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …

Neoantigens derived from somatic mutations are specific to cancer cells and are ideal
targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and …

Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …

Therapeutic antibodies are the largest class of biotherapeutics and have been successful in
treating human diseases. However, the design and discovery of antibody drugs remains …

Motivation: Peptides have recently emerged as promising therapeutic agents against
various diseases. For both research and safety regulation purposes, it is of high importance …

Background Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma
(ccRCC) that reflects the trajectory of evolution and influences clinical prognosis. Here, we …